Prognose

Das durchschnittliche Kursziel der Analysten beträgt +4,56€(+75,38%). Der Median liegt bei +4,56€(+75,38%).

Kaufen	6
Halten	0
Verkaufen	0

Scoring-Modelle

Dividenden-Strategie	0 / 15
HGI-Strategie	3 / 18
Levermann-Strategie	-7 / 13

News

Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2024 and provided a business update. “Completing submission of the BLA is an important milestone in potentially addressing the significant unmet need of people living with aPAP, a rare and debilitating lung disease,” said Matt Pauls, Chair and Chief Executive.» Mehr auf businesswire.com
Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has entered into a loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC), for up to $200 million. Access to the additional capital strengthens Savara's balance sheet following the submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a tre.» Mehr auf businesswire.com
Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has completed submission of the BLA to the FDA for MOLBREEVI as a treatment for aPAP. “Submission of the BLA marks an important milestone for the Company and the aPAP community,” said Matt Pauls, Chair and Chief Executive Officer, Savara. “We believe this unprecedented body of data demonstrates MOLBREEVI improves pulm.» Mehr auf businesswire.com

Unternehmenszahlen

Im letzten Quartal hatte Savara Inc einen Umsatz von 261,40k€ und ein Nettoeinkommen von −27,91 Mio€

(EUR)	Dez. 2024	YOY
Umsatz	+261,40k	-
Bruttoeinkommen	+130,70k	318,91%
Nettoeinkommen	−27,91 Mio	91,66%
EBITDA	−29,93 Mio	88,36%

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+474,13 Mio€
Anzahl Aktien	172,63 Mio
52 Wochen-Hoch/Tief	+4,87€ - +2,06€
Dividenden	Nein
Beta	0,6
KGV (PE Ratio)	−6,22
KGWV (PEG Ratio)	−0,06
KBV (PB Ratio)	+3,48
KUV (PS Ratio)	+1.910,39

Unternehmensprofil

Savara Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich auf seltene Atemwegserkrankungen konzentriert. Sein führender Produktkandidat ist Molgramostim, ein inhalativer Granulozyten-Makrophagen-Kolonie-stimulierender Faktor, der sich in der Phase III der Entwicklung zur Behandlung der autoimmunen pulmonalen alveolären Proteinose befindet. Der Hauptsitz des Unternehmens befindet sich in Austin, Texas.